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Chapter 4   
 
18F-fluoroestradiol positron emission tomography (FES PET) has 
added value in staging and therapy decision making in patients with 
disseminated lobular breast cancer 
C.M. Venema1, E.F.J. de Vries2, A.W.J.M Glaudemans2, B.J. Poppema1, G.A.P. 
Hospers1, C.P. Schröder1 
1Department of Medical Oncology, 2Department of Nuclear Medicine and 
Molecular Imaging, University Medical Center Groningen, University of 
Groningen, Groningen, The Netherlands. 
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Lobular breast cancer (LBC) is the second most common type of invasive 
breast cancer, accounting for almost ten percent of the invasive lesions. LBC 
lesions are often difficult to detect with conventional imaging, as they tend 
to grow less cohesively than the more common ductal cancer. In this case 
series we present four patients with LBC, in whom confirmation of 
metastatic disease would make the crucial difference between curative or 
non-curative treatment. Staging with conventional imaging, however, 
yielded equivocal results, and a biopsy was not feasible. In contrast, 16α-
18F-fluoro-17β-estradiol (FES) PET provided a decisive contribution to 
clinical decision making in these patients with LBC. This indicates that FES-
PET may have added value in relation to conventional staging in LBC and 
may support in clinical decision making.  
 
Keywords: FES-PET, lobular breast cancer, estrogen receptor 
517613-L-sub01-bw-Venema




Lobular breast cancer (LBC) accounts for almost 10% of the invasive breast 
cancer lesions. These tumors originate from lobules and have different 
appearances than ductal carcinoma. Patients with LBC tend to have a better 
prognosis than patients with ductal breast cancers (DBC), at similar disease 
stages [1]. LBC is more difficult to detect compared to DBC, as LBC usually 
does not present as a lump. Loss of cell adhesion protein E-cadherin in LBC 
induces diffuse growth, often into the stroma without a significant 
desmoplastic reaction [2]. This diffuse growth pattern also applies to 
metastasis in the gastrointestinal tract, which makes LBC metastases often 
difficult to detect by physical examination and conventional imaging. The 
abundant expression of the estrogen receptor (ER) by nearly all LBCs 
renders molecular imaging of the ER particularly suitable for detection of 
LBCs metastases. The estrogen derivative 16α-[18F]fluoro-17β-estradiol 
(FES) is a tracer used for positron emission tomography (PET) imaging in 
several studies to detect ER expression in tumors. FES PET has a high 
sensitivity (84%) and specificity (98%) for ER-positive tumors [3]. At the 
University Medical Center Groningen we often perform FES-PET in patients 
with a clinical dilemma [5].  
Here we present four patients with LBC and inconclusive standard work-up, 
in whom confirmation of metastatic disease would make the crucial 
difference between curative and non-curative treatment. The examples 
demonstrate the important contribution FES PET can have in de diagnostic 
work-up of LBC. FES-PET images were all obtained from the skull to mid-
thigh with a 64-slice PET/CT camera (Biopgraph mCT, Siemens Medical 
Systems, Knoxville, TN). A low-dose CT-scan was used for attenuation 
correction. The whole body PET-scan was acquired 60 minutes after 
intravenous injection of approximately 200 MBq FES. 
Case 1 A 72 year old patient was diagnosed with LBC 12 years prior to 
referral, for which she underwent breast amputation and consecutive 
radiotherapy. At the time of referral, a local recurrence in the amputation 
scar was excised. Excision margins were focally positive for tumor cells. The 
patient could be treated with a curative intent by hyperthermia and 
radiotherapy if no distant metastases were present. Contrast enhanced CT 
revealed sclerosis of thoracic vertebra 7 and the iliac bone, suggesting 
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metastatic lesions. These lesions, however, were not confirmed by bone 
scintigraphy or 18F-fluorodeoxyglucose (FDG) PET. The bone scan did show 
one skull lesion, which could not be confirmed by FDG PET (Fig 1). FDG-PET 
showed only increased uptake at the excision site due to the recent 
surgery. Because of the discrepancy between the different conventional 
imaging modalities, a FES-PET was performed, which showed high tracer 
uptake in multiple bone lesions and lymph nodes throughout the body (Fig. 
1). FES-PET could not detect remnants of the local recurrence. The focally 
present cells were either below the detection limit of the FES-PET or FDG 
PET was false positive due to tissue repair after surgery. The skull lesion 
visible on the bone scan was not visible on the FES-PET scan. Since FDG-PET 
was also negative, this was presumably a non-malignant hyperostosis 
lesion.  
 
Figure 1: whole body conventional bone scan (left, anterior and posterior view) of 
case 1 showing one focal lesion in the skull (arrow 1): a bone metastasis cannot be 
excluded. FDG PET (A) shows only uptake at the site of the recently excised local 
recurrence (arrow 2). FES PET (B) shows multiple bone metastases and lymph node 
metastases in the mediastinum (arrow 3), but no uptake at the site of the local 
recurrence (arrow 2).  
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In conclusion, FES-PET findings were compatible with LBC metastases in 
lymph nodes and bone. Anastrozole treatment was started as first line 
palliative hormone therapy. Treatment evaluation was based on clinical 
findings and biochemical evaluations, because lesions were not visible on 
conventional imaging. At follow-up after eight months of treatment, the 
patient showed good clinical response. 
Case 2 A 70 year old patient had been diagnosed with an occult LBC with 
axillary lymph node metastases prior to referral. She had complaints of back 
pain and laboratory results showed anemia (6.4 mmol/l). On a diagnostic 
CT-scan of the thorax and abdomen diffuse inhomogeneous skeletal 
findings were found and considered non-malignant. FDG-PET scan showed 
slightly elevated uptake at the malignant lymph nodes and multiple bone 
foci, of which further differentiation between malignancy and degenerative 
or traumatic changes was not possible. More lymph nodes and bone lesions 
were detected by FES-PET than  by FDG-PET. Furthermore diffuse uptake 
was visible in the bone marrow. Based on the FES-PET findings an additional 
bone marrow biopsy was performed. The bone marrow was diffusely 
infiltrated with LBC (Fig. 2). In conclusion, the FES-PET was compatible with 
bone marrow and bone metastases from LBC, in addition to the known 
lymph node metastases. The patient received tamoxifen after which she 
showed good biochemical and clinical response for more than one year. 
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Figure 2: FDG PET of case 2 (part A) shows pathological lymph nodes, as well as 
diffuse bone uptake, considered to be either degenerative, traumatic or metastatic 
disease. FES PET shows uptake in axillary, hilar, and mediastinal lymph nodes and 
diffuse bone uptake indicating ER-positive uptake.  
 
Case 3 A 54 year old patient was diagnosed with T2N0M0 LBC one year 
prior to referral. She underwent breast amputation and consecutive 
chemo-radiation therapy, and was on adjuvant hormonal treatment at time 
of referral. She had complaints of her left hip, which on additional imaging 
showed a solitary lesion of uncertain significance in the left femur on both 
bone scintigraphy and the MRI scan. Because of this diagnostic uncertainty, 
the patient was referred for a FES-PET. This scan was performed one month 
after the MRI scan and showed no uptake in the femur lesion nor any other 
lesions (Fig. 3). Therefore, the FES-PET did not support the presence of ER-
positive metastases, and the patient continued her adjuvant hormonal 
treatment. Complaints resolved spontaneously and a follow-up MRI could 
no longer identify the femur lesion (Fig 3C).  
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Figure 3: FES PET of case 3 shows physiological uptake, but no abnormal uptake in 
hip area or any other part of the body (A). MRI shows a lesion in the left caput 
femoris prior to FES PET (B, arrow), which spontaneously resolved after 3 months 
(C, arrow) 
 
Case 4:  A 72 year old patient was diagnosed with T3N2M0 LBC 8 years prior 
to referral. She underwent breast amputation and consecutive chemo-
radiation therapy, followed by adjuvant hormonal treatment. After 5 years 
of treatment, adjuvant hormonal treatment was stopped according to the 
guidelines. After cessation of adjuvant treatment she started suffering from 
diffuse skeletal pain. Restaging with CT showed one lesion in the eighth 
thoracic vertebral body, but no other sites suspect for metastases. A biopsy 
of this lesion was considered unsafe due to the location. Therefore, a FES-
PET was requested to assess the presence of ER-positive disease. In line 
with the CT, the FES-PET showed uptake in the vertebral lesion, without 
uptake anywhere else (Fig. 4). She was considered to have an 
oligometastasis and underwent curative radiation treatment (16 Gy) of the 
lesion. Now 2 years later, there is still no evidence of disease.  
 
517613-L-sub01-bw-Venema





Figure 4: FES PET of case 4 shows  high uptake in one vertebral lesion (A, arrow), 
indicating oligometastasis. CT scan showed a single sclerotic bone lesion at thoracic 
vertebra (B, arrow). 
Staging lobular breast cancer patients with conventional imaging  
Although it is more difficult to detect LBC, current Comprehensive Cancer 
Network Guidelines (NCCN) on screening and staging breast cancer patients 
do not differentiate between LBC and DBC [6]. Mammography has a high 
false negative rate of about 30% to detect LBC [7]. LBC lesions mostly 
manifest as architectural distortions and calcifications are detected less 
frequently [7-9]. At the time of diagnosis, patients with LBC often present 
with a larger tumor size and higher stage compared to patients with ductal 
breast cancer [10]. Ultrasound is performed for staging tumors when 
lesions are found by mammography or when a lump is palpable, and 
ultrasound therefore has a sensitivity of 98%, similar to ductal breast cancer 
[7]. MRI has a sensitivity up to 96% to detect LBC, similar to the overall 
detection of primary breast cancer [8]. FDG uptake in LBC primary lesions is 
lower compared to ductal breast cancer and may result in false-negative 
results in LBC patients [11,12].  
 In Table 1 more details on sensitivity for detection of breast cancer overall 
and LBC are provided.  
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Metastatic LBC tends to spread mostly to the bone, similar to ductal breast 
cancer, resulting in both sclerotic and lytic bone lesions. Sclerotic lesions 
can be detected by conventional bone scintigraphy, but for lytic lesions, 
FDG-PET is preferable [13]. However bone metastases in LBC patients have 
lower FDG uptake compared to those with ductal breast cancer [14,15]. 
Apart from bone lesions, LBC also causes metastases in gastrointestinal 
tract, peritoneum and reproductive organs more often than ductal breast 
cancer. On CT, gastrointestinal tract metastases usually are observed as 
general wall thickening rather than a solid mass. With the conventional 
imaging modalities it is thus difficult to recognize LBC both in early disease- 
and in the metastatic setting.  
Table 1: Sensitivity of imaging modalities for detection of breast cancer 
overall and lobular breast cancer in particular 









Mammography Primary  60-98% 11-81% 7, 8 
Ultrasound Primary 68-98% 90% 7, 8 
MRI breast Primary 90-98% 93-95% 8, 9 
FDG PET  Primary 78-91% 75% 11, 12, 20 
FDG PET Metastatic 93-95% 43% -100% 13, 14 
Bone 
scintigraphy  
Metastatic 82-91% Unknown 15, 16 
Discussion  
Since LBC is usually ER-positive, FES-PET could be of help to assess bone and 
nodal metastases. Due to high physiological uptake of FES in the liver, and 
excretion via the bile, FES-PET is not the optimal imaging technique to 
detect liver and intestinal metastases. However, in case of equivocal lesions 
or suspected metastatic disease outside of the liver and intestines, FES-PET 
could be of help in staging the patient with LBC, for better understanding 
the course of the disease and to guide treatment decision making.  
This is to our knowledge the first case series indicating  that FES-PET can 
have  clear impact on clinical decision making in LBC, when other imaging 
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techniques show equivocal results. This early clinical finding will have to be 
confirmed in larger prospective studies.  
 
Conclusion 
FES PET can provide crucial information for patients with LBC and referring 
physicians regarding disease stage, which can profoundly affect treatment 
decisions and thus prognosis.   
 
List of abbreviations:  
FES: 16α-[18F]fluoro-17β-estradiol 
FDG: 2’-[18F]fluoro-2’-deoxyglucose 
LBC: lobular breast cancer 
DBC: ductal breast cancer 
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